Alzheimer's Disease

Recommendations for Aduhelm require more guidance and an expanded clinical profile to address several issues that will aid in discussions between patients and providers, per a systematic review of clinical data published in Neurology.

Healio’s most-viewed neurology stories in February highlight evidence of potential dangers of marijuana for brain health, the FDA expanding the indication of a hemorrhage detection device and an NIH grant to a biotech firm.

Acadia Pharmaceuticals Inc. has resubmitted its supplemental new drug application to the FDA for pimavanserin for treating hallucinations and delusions linked to Alzheimer’s disease psychosis.

Swiss-based biopharmaceutical company AC Immune SA announced promising new interim data on the safety and efficacy of its ACI-35.030 vaccine for patients with early Alzheimer’s disease, according to a company press release.

Publicity surrounding FDA approval of Aduhelm for Alzheimer’s disease did not contribute to understanding of nor enthusiasm for the drug among middle-aged and older adults, according to survey results published in JAMA Network Open.

Evidence of amyloid abnormality across the Alzheimer’s disease spectrum is more prevalent with cerebrospinal fluid testing, according to a cross-sectional, individual-participant pooled study published in JAMA Neurology.

The National Institute of General Medical Sciences, a division of the NIH, awarded $1.8 million to Integrated Micro-Chromatography Systems Inc. for phase 2 of its fast track Small Business Innovation Research grant, according to a release.

Cognito Therapeutics and Providence Health Plan will collaborate on a phase 3 study of a noninvasive therapy for patients with mild cognitive impairment, according to a release.

Healio’s most-viewed neurology stories in January highlight several FDA developments, a Medicare proposal to limit Aduhelm coverage and a study on the role of Epstein-Barr virus infection in MS.

There is increasingly strong evidence that traumatic brain injuries raise the risk for future Alzheimer’s disease.